Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination insulin glargine 100 U/mL (iGlar) lixisenatide (Lixi), has been shown provide robust HbA1c reductions allowing more people targets compared with separate administration iGlar or Lixi. The purpose this review is help clinicians understand treatment using iGlarLixi by presenting typical clinical scenarios supported research evidence. These cases will focus on individuals T2D inadequately controlled oral antihyperglycemic drugs, basal insulin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), take into consideration duration, body mass index, incidence adverse events, regimen simplicity. Clinical evidence the efficacy, effectiveness, safety from randomized trials real-world studies be discussed in context these cases.